Leukotrienes
Subfamily A5 of the GPCRs consist of seven members of receptors that are activated by either neuropeptides or leukotriene-derivatives (galanin, leukotrienes and cysteinyl leukotrienes, relaxin, melanin, urotensin, and kisspeptin (a.k.a. metastin). The cysteinyl leukotrienes (cys-LTs) are a family of potent bioactive lipids that act through two structurally divergent GPCRs, termed the CysLT1 and CysLT2. Their endogenous ligands are LTC4, LTD4, and LTE4 are peptide-conjugated lipids that are prominent products of activated eosinophils, basophils, mast cells (MCs), and macrophages. These leukotrienes are commonly recognized as potent inflammatory mediators that initiate and propagate a diverse array of biologic responses. Consequently, clinically efficacious receptor antagonists and inhibitors of cys-LT synthesis have been introduced to treat asthma, immune responses, inflammation, tissue repair, and fibrosis[1].
[1] Y Kanaoka et al. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol. 2004 Aug 1;173(3):1503-10.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
2620 | Quininib | Antagonist of the cysteinyl leukotriene receptor (CysLT1 and -2) | €95.00 | |
3236 | Montelukast sodium | Potent and selective CysLT1 receptor antagonist | €70.00 | |
2738 | CysLT1 Antagonist Q8 | Antagonist of the cysteinyl leukotriene receptor 1 (CysLT1) | €95.00 |